Skip to main content
Caplight Logo









Cure Genetics

Cure Genetics

Private
SuzhouHealthcare & Life Scienceshttps://curegenetics.com/

Last Round

Series B

Jan 5, 2022

Total Funding Raised

$79.2M

Company Overview

Cure Genetics is a biotechnology company that develops cell and gene therapies for solid tumors and genetic diseases using its proprietary AIMS CAR-NKT and VELP AAV platforms.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

gene therapycell therapyCRISPRgene editingbiotech platformAAV vectorCAR-NKTsolid tumor therapygenetic disease treatmentdrug discoveryprecision medicinebiotech licensingnext-gen therapeuticsviral vector engineeringadvanced therapies

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Cure Genetics Comparables

Compare Cure Genetics with similar companies based on industry and business-model similarity.

Cure Genetics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
EdiGene
81%
ImmunoKite Therapeutics
77%
Metagenomi
76%

Cure Genetics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJan 5, 2022
Series AAug 6, 2018
AngelJan 1, 2017

Key People

Founding team and executive leadership

徐元元

创始人&CEO

Executive Team

Li Ren

Chief Technology Officer

Executive Team

Cure Genetics Investors

Notable investors and investment history

Cure Genetics investors
InvestorRounds
Oriza HoldingsSeries B
Blue Ocean Capital GroupSeries B
Advantech CapitalSeries B
Qiming Venture PartnersSeries B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 6, 2018

    $17M round led by Qiming Venture Partners

Cure Genetics Filings

Explore SEC and related filing metadata, where available.

Cure Genetics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Cure Genetics's valuation, stock price, and market status.

Is Cure Genetics a public or private company?

Cure Genetics is a private company.

What is the current stock price of Cure Genetics?

Cure Genetics is a private company with no public stock price. No recent secondary market data is available.

How much is Cure Genetics worth (valuation)?

Valuation information for Cure Genetics is not publicly available.

Can I buy Cure Genetics stock?

Cure Genetics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Cure Genetics's last funding round?

Cure Genetics's most recent funding round was Series B on January 5, 2022.

Who are the main investors in Cure Genetics?

Key investors in Cure Genetics include Advantech Capital, Qiming Venture Partners.

Will Cure Genetics IPO soon?

No public IPO plans have been announced for Cure Genetics.

How can I track Cure Genetics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Cure Genetics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSuzhou
Employee Range13
Year Founded2016
Last FundingJan 5, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?